The company is located in Taizhou, a coastal port city in central Zhejiang, with a pleasant climate in the east. At present, the company's total assets have reached 700 million yuan. The Group owns holding subsidiaries such as Zhejiang Haizheng Pharmaceutical Co., Ltd., Zhejiang Haizheng Chemical Co., Ltd., Zhejiang Jiangnan Pharmaceutical Factory and Jiaojiang Thermal Power Co., Ltd., with sales income of 400-800 million yuan, profits and taxes of 9,465,438+million yuan and per capita annual income of 65,438+. Zhejiang Haizheng Pharmaceutical Co., Ltd., the core enterprise of the company, mainly produces more than 40 kinds of drugs in four series: anti-tumor, anti-infection, anti-parasite and cardiovascular. With scientific management, advanced technology and first-class equipment to ensure product quality, Haizheng Pharmaceutical became the first pharmaceutical enterprise in Zhejiang Province to pass the IS09002 quality assurance system certification, and the company obtained the French ATN management system model certification. At present, the company has 8 products to fill the domestic gap, 4 national new products, 5 products such as adriamycin, ivermectin and daunorubicin have passed FDA certification (US Food and Drug Administration), and more than 75% of the products are exported to more than 30 countries and regions such as Europe and America. Haizheng Pharmaceutical, as a national high-tech enterprise, was listed on the Shanghai Stock Exchange on July 25th, 2000.